A biosimilar is a biological medicinal product that is highly similar to an already authorized original biological medicinal product. The introduction of biosimilars may allow for a reduction in health care costs, due to discount pricing. Current clinical studies and real-world data suggest that the biosimilar SB4 is equivalent to etanercept with respect to efficacy and safety. Additional real-world safety data for SB4 via pharmacovigilance studies are needed to draw conclusions regarding the risks of rare adverse events such as serious infections and malignancy. Clinical trial design of biosimilars should be standardised to improve consistency, increase confidence and facilitate interpretation of data. Where there are health economic advantages of switching from originator to biosimilar, patients should be appropriately informed, and, ideally, in order to minimise nocebo responses and maximise benefit, switching should be undertaken by shared decision-making between the physician a...
The word encryption comes from the Greek word kryptos, meaning hidden or secret. The use of encryption is nearly as old as the art of communication itself. As early as 1900 BC, an Egyptian scribe used non-standard hieroglyphs to hide the meaning of an inscription. In a time when most people couldn't read, simply writing a message was often enough, but encryption schemes soon developed to convert messages into unreadable groups of figures to protect the message's secrecy while it was carried from one place to another. The contents of a message were reordered (transposition) or replaced (substitution) with other characters, symbols, numbers or pictures in order to conceal its meaning. In cryptography, encryption is the process of encoding messages or information in such a way that only authorized parties can read it. Encryption does not of itself prevent interception, but denies the message content to the interceptor. In an encryption scheme, the intended communication informa...